Onyx Pharmaceuticals (ONXX) - Bull Of The Day
By Zacks Investment Research on February 25, 2009 | More Posts By Zacks Investment Research | Author's Website
Nexavar sales in the fourth quarter of 2008 remained strong for Onyx Pharmaceuticals, Inc. (ONXX). This is mainly attributed to the market penetration in the liver cancer market, while Nexavar market share in kidney cancer market has stabilized due to heavy competition from Pfizer (PFE) and Wyeth (WYE).
We expect continued Nexavar sales growth in 2009 and over the next several years since the label has expanded to liver cancer. In addition to the US and EU, Nexavar has been approved in South Korea and China for liver cancer.
Nexavar will achieve blockbuster status in 2010. We maintain our Buy rating on Onyx shares with a price target of $45 per share.
If you like this article please...
Leave A Comment :
Recent Market Opinions:
There Is A Considerable Gap Between What The Fed’s Saying And What It’s Thinking
S&P 500 Flat Over The Week As Investors Reflect On Prices Versus Fundamentals
What’s Triggering America’s Populist Rage?
China Will Blow Up Before It Grows Up
Financial ETFs Still Remain Vulnerable
Recent News:
European Economics Preview: Eurozone Flash PMI Due - 10 mins ago
New Zealand’s ANZ-Roy Morgan Consumer Confidence Falls In November - 32 mins ago
*New Zealand Nov. Consumer Confidence Down 4.4 Points To 121.5 - 54 mins ago
Singapore October Consumer Prices Drop More Than Expected - 1 hr ago
Thai Economy Grows For Second Consecutive Quarter - 1 hr ago
Opinions From Our Contributors


